Drug Profile
Research programme: inflammatory disorder therapeutics - AstraZeneca/University System of Maryland
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune; University System of Maryland
- Developer AstraZeneca; University System of Maryland
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Respiration disorders
Most Recent Events
- 28 May 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 May 2018 No recent reports of development identified for research development in Inflammation in USA
- 28 May 2018 No recent reports of development identified for research development in Respiration-disorders in USA